Display options
Cite
den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol. 2013;3:250doi: 10.3389/fonc.2013.00250.
den Hollander, P., Savage, M. I., & Brown, P. H. (2013). Targeted therapy for breast cancer prevention. Frontiers in oncology, 3250. https://doi.org/10.3389/fonc.2013.00250
den Hollander, Petra, et al. "Targeted therapy for breast cancer prevention." Frontiers in oncology vol. 3 (2013): 250. doi: https://doi.org/10.3389/fonc.2013.00250
den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol. 2013 Sep 23;3:250. doi: 10.3389/fonc.2013.00250. PMID: 24069582; PMCID: PMC3780469.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2013 Sep 23;3:250. doi: 10.3389/fonc.2013.00250.

Targeted therapy for breast cancer prevention.

Frontiers in oncology

Petra den Hollander, Michelle I Savage, Powel H Brown

Affiliations

  1. Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center , Houston, TX , USA.

PMID: 24069582 PMCID: PMC3780469 DOI: 10.3389/fonc.2013.00250

Abstract

With a better understanding of the etiology of breast cancer, molecularly targeted drugs have been developed and are being testing for the treatment and prevention of breast cancer. Targeted drugs that inhibit the estrogen receptor (ER) or estrogen-activated pathways include the selective ER modulators (tamoxifen, raloxifene, and lasofoxifene) and aromatase inhibitors (AIs) (anastrozole, letrozole, and exemestane) have been tested in preclinical and clinical studies. Tamoxifen and raloxifene have been shown to reduce the risk of breast cancer and promising results of AIs in breast cancer trials, suggest that AIs might be even more effective in the prevention of ER-positive breast cancer. However, these agents only prevent ER-positive breast cancer. Therefore, current research is focused on identifying preventive therapies for other forms of breast cancer such as human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC, breast cancer that does express ER, progesterone receptor, or HER2). HER2-positive breast cancers are currently treated with anti-HER2 therapies including trastuzumab and lapatinib, and preclinical and clinical studies are now being conducted to test these drugs for the prevention of HER2-positive breast cancers. Several promising agents currently being tested in cancer prevention trials for the prevention of TNBC include poly(ADP-ribose) polymerase inhibitors, vitamin D, and rexinoids, both of which activate nuclear hormone receptors (the vitamin D and retinoid X receptors). This review discusses currently used breast cancer preventive drugs, and describes the progress of research striving to identify and develop more effective preventive agents for all forms of breast cancer.

Keywords: TNBC; breast; cancer; prevention; therapy

References

  1. Lancet Oncol. 2008 Jan;9(1):45-53 - PubMed
  2. Nat Rev Drug Discov. 2006 Aug;5(8):671-88 - PubMed
  3. Cancer. 2010 Jan 15;116(2):292-301 - PubMed
  4. Br J Cancer. 2002 Feb 12;86(4):540-5 - PubMed
  5. Cell Cycle. 2010 Jan 1;9(1):188-97 - PubMed
  6. J Clin Oncol. 2005 Dec 1;23(34):8606-12 - PubMed
  7. Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):114-9 - PubMed
  8. Int J Cancer. 2007 Aug 15;121(4):856-62 - PubMed
  9. Cancer Res. 2002 Oct 1;62(19):5405-7 - PubMed
  10. JAMA. 2006 Jun 21;295(23):2727-41 - PubMed
  11. J Natl Cancer Inst. 2007 May 2;99(9):727-37 - PubMed
  12. Lancet Oncol. 2012 Feb;13(2):135-44 - PubMed
  13. J Natl Cancer Inst. 2009 Jan 21;101(2):107-13 - PubMed
  14. J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61 - PubMed
  15. N Engl J Med. 2010 Feb 25;362(8):686-96 - PubMed
  16. JAMA Intern Med. 2013 Mar 11;173(5):355-61 - PubMed
  17. Cancer Res. 2002 Jan 1;62(1):122-8 - PubMed
  18. Clin Cancer Res. 2009 Oct 15;15(20):6327-40 - PubMed
  19. Breast Cancer Res Treat. 2010 Jan;119(2):477-84 - PubMed
  20. Nat Rev Cancer. 2005 May;5(5):341-54 - PubMed
  21. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 - PubMed
  22. Cancer Causes Control. 1994 Nov;5(6):491-500 - PubMed
  23. Clin Cancer Res. 2004 Dec 1;10(23):8059-67 - PubMed
  24. Clin Cancer Res. 2011 Apr 15;17(8):2314-27 - PubMed
  25. Breast J. 2005 Jul-Aug;11(4):278-80 - PubMed
  26. Breast. 2009 Aug;18 Suppl 2:S1-11 - PubMed
  27. J Exp Med. 1925 Nov 30;42(6):753-77 - PubMed
  28. Anticancer Res. 2009 Apr;29(4):1143-50 - PubMed
  29. Bull Exp Biol Med. 2005 Jun;139(6):721-3 - PubMed
  30. Mol Carcinog. 2013 Jun;52(6):446-58 - PubMed
  31. Mol Cells. 2013 Mar;35(3):219-25 - PubMed
  32. N Engl J Med. 2006 Jul 13;355(2):125-37 - PubMed
  33. J Clin Oncol. 2012 Jul 20;30(21):2593-600 - PubMed
  34. Cancer Res. 2002 Nov 15;62(22):6376-80 - PubMed
  35. Cancer. 2011 Jan 1;117(1):39-47 - PubMed
  36. Cancer Biol Ther. 2004 Aug;3(8):772-5 - PubMed
  37. J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):242-5 - PubMed
  38. Breast Cancer (Auckl). 2013;7:7-22 - PubMed
  39. N Engl J Med. 2009 Jul 9;361(2):123-34 - PubMed
  40. J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33 - PubMed
  41. Br J Cancer. 2008 Apr 22;98(8):1380-8 - PubMed
  42. Cancer Res. 2006 Jan 1;66(1):362-71 - PubMed
  43. Br J Cancer. 1989 Jul;60(1):126-31 - PubMed
  44. Breast Cancer Res Treat. 2012 Aug;135(1):261-9 - PubMed
  45. BMC Complement Altern Med. 2013 Jan 08;13:6 - PubMed
  46. J Clin Oncol. 2008 Jul 10;26(20):3426-33 - PubMed
  47. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 - PubMed
  48. Cancer Prev Res (Phila). 2010 Jun;3(6):696-706 - PubMed
  49. J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62 - PubMed
  50. Mol Cancer Ther. 2006 Jun;5(6):1452-8 - PubMed
  51. Cancer Causes Control. 2011 Jan;22(1):125-34 - PubMed
  52. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
  53. Genes Dev. 2004 Aug 15;18(16):1926-45 - PubMed
  54. Breast Cancer Res. 2010;12(5):R68 - PubMed
  55. Cancer. 2012 May 15;118(10):2594-602 - PubMed
  56. Expert Rev Clin Pharmacol. 2012 Nov;5(6):701-9 - PubMed
  57. Cancer Prev Res (Phila). 2012 Oct;5(10):1195-202 - PubMed
  58. Immunotherapy. 2010 Mar;2(2):213-26 - PubMed
  59. Int J Cancer. 2008 Apr 15;122(8):1722-9 - PubMed
  60. Nature. 2005 Apr 14;434(7035):913-7 - PubMed
  61. Clin Cancer Res. 2009 Jan 1;15(1):226-37 - PubMed
  62. Lancet. 2002 Sep 14;360(9336):817-24 - PubMed
  63. J Natl Cancer Inst. 2008 Oct 15;100(20):1439-47 - PubMed
  64. Annu Rev Med. 2002;53:35-57 - PubMed
  65. Gastroenterology. 2006 Dec;131(6):1674-82 - PubMed
  66. PLoS One. 2013;8(2):e56567 - PubMed
  67. Am J Pathol. 2012 Jul;181(1):278-93 - PubMed
  68. Cell Death Differ. 2004 Dec;11 Suppl 2:S126-43 - PubMed
  69. J Clin Oncol. 2001 May 15;19(10):2754-63 - PubMed
  70. Br J Cancer. 2013 May 28;108(10):2172-7 - PubMed
  71. Clin Transl Oncol. 2007 Aug;9(8):484-93 - PubMed
  72. Cancer Res. 2006 Sep 1;66(17):8707-14 - PubMed
  73. Cancer Res. 2006 Dec 1;66(23):11381-8 - PubMed
  74. Curr Opin Genet Dev. 2010 Feb;20(1):87-90 - PubMed
  75. Breast Cancer Res Treat. 2010 Jan;119(1):137-44 - PubMed
  76. Br J Cancer. 2001 May 4;84(9):1188-92 - PubMed
  77. IDrugs. 2010 Sep;13(9):646-56 - PubMed
  78. Cancer Res. 2006 Nov 1;66(21):10269-73 - PubMed
  79. N Engl J Med. 2011 Jun 23;364(25):2381-91 - PubMed
  80. Lancet. 1998 Jul 11;352(9122):98-101 - PubMed
  81. Breast Cancer Res. 2008;10(6):R99 - PubMed
  82. Clin Breast Cancer. 2009 Feb;9(1):45-50 - PubMed
  83. J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71 - PubMed
  84. Breast Cancer Res Treat. 2011 Feb;126(1):215-20 - PubMed
  85. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 - PubMed
  86. N Engl J Med. 2005 Mar 17;352(11):1071-80 - PubMed
  87. Nat Rev Cancer. 2004 May;4(5):335-48 - PubMed
  88. Cell Cycle. 2009 Jan 1;8(1):88-96 - PubMed
  89. Menopause. 2003 Jul-Aug;10(4):332-6 - PubMed
  90. Methods Enzymol. 2006;409:493-510 - PubMed
  91. J Clin Oncol. 2006 May 1;24(13):2127; author reply 2127-8 - PubMed
  92. JAMA. 1999 Jun 16;281(23):2189-97 - PubMed
  93. Recent Results Cancer Res. 2011;188:147-62 - PubMed
  94. N Engl J Med. 2000 Jun 29;342(26):1946-52 - PubMed
  95. Semin Oncol. 2010 Jun;37(3):258-81 - PubMed
  96. Breast Cancer Res Treat. 2012 Oct;135(3):821-30 - PubMed
  97. Gynecol Oncol. 2002 Jul;86(1):24-7 - PubMed
  98. Eur J Cancer. 2013 Jul;49(10):2284-93 - PubMed
  99. Recent Results Cancer Res. 2003;163:96-103; discussion 264-6 - PubMed
  100. Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9 - PubMed
  101. PLoS One. 2010 Sep 10;5(9): - PubMed
  102. J Natl Cancer Inst. 1999 Nov 3;91(21):1847-56 - PubMed
  103. J Steroid Biochem Mol Biol. 2003 Oct;87(1):35-45 - PubMed
  104. Breast Cancer Res Treat. 2012 Feb;131(3):915-24 - PubMed
  105. Biochem Biophys Res Commun. 2013 Mar 1;432(1):123-8 - PubMed
  106. J Natl Cancer Inst. 2007 Feb 21;99(4):283-90 - PubMed
  107. Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74 - PubMed
  108. Lancet. 1998 Jul 11;352(9122):93-7 - PubMed
  109. N Engl J Med. 2012 Feb 9;366(6):520-9 - PubMed
  110. J Natl Cancer Inst. 2007 Feb 21;99(4):272-82 - PubMed
  111. Clin Breast Cancer. 2007 Dec;7(11):895-900 - PubMed
  112. Epidemiology. 2002 May;13(3):262-7 - PubMed
  113. N Engl J Med. 1990 Sep 20;323(12):795-801 - PubMed
  114. Cancer Res. 1979 Apr;39(4):1339-46 - PubMed
  115. Mol Endocrinol. 2011 Mar;25(3):516-28 - PubMed
  116. Cancer Prev Res (Phila). 2012 Sep;5(9):1144-54 - PubMed
  117. Genome Biol. 2007;8(5):R76 - PubMed
  118. Breast Cancer Res Treat. 2011 Aug;128(3):783-94 - PubMed
  119. N Engl J Med. 2006 Aug 31;355(9):885-95 - PubMed
  120. Lancet. 2011 Aug 27;378(9793):771-84 - PubMed
  121. Expert Rev Anticancer Ther. 2008 Sep;8(9):1377-85 - PubMed
  122. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  123. Cancer Prev Res (Phila). 2012 Aug;5(8):1036-43 - PubMed
  124. J Natl Cancer Inst. 2008 Jun 18;100(12):854-61 - PubMed
  125. Clin Cancer Res. 2007 Oct 15;13(20):6224-31 - PubMed
  126. Ann Oncol. 2006 Jul;17(7):1065-71 - PubMed
  127. J Clin Invest. 2011 Jul;121(7):2750-67 - PubMed
  128. Clin Cancer Res. 2000 Sep;6(9):3696-704 - PubMed
  129. Curr Oncol. 2007 Jun;14(3):89-96 - PubMed
  130. Lancet. 2012 Nov 17;380(9855):1778-86 - PubMed
  131. Lancet. 2003 Jan 25;361(9354):296-300 - PubMed
  132. Science. 2005 Dec 9;310(5754):1642-6 - PubMed

Publication Types

Grant support